The aim of the present study was to evaluate the dose- and time-dependence of the effect displayed by doxorubicin (DXR) on the electrocardiogram (ECG) and to establish the relationship between structural alterations of the myocardium and ECG changes in rats administered DXR, at a dose of 1.5 or 3.0 mg/kg, every 3 days for a total of three administrations. The most interesting findings consisted of a dose-dependent, but reversible prolongation of the QRS complex, and in a dose-dependent and progressive irreversible increase in QaT and, in particular, in SaT duration. Furthermore, animals treated with the higher DXR dose showed a slight increase in serum K+ concentration and a significant decrease in serum Ca2+ levels. A good correlation was found between the morphologic score indicating the degree of observed tissue damage and SaT prolongation. These results therefore support the usefulness of measuring this ECG parameter for monitoring the development of DXR-induced cardiotoxicity in rats.
BachmannE., WeberE., ZbindenG.: Effects of seven anthracycline antibiotics on electrocardiogram and mitochondrial function of rat hearts. Agents Actions, 5: 383–393, 1975.
3.
BeinfieldW.H., LehrD.: QRS-T variations in the rat electrocardiogram. Am. J. Physiol., 214: 197–204, 1968.
4.
BillinghamM.E.: Endomyocardial changes in anthracycline-treated patients with and without irradiation. Front. Radiat. Ther. Oncol., 13: 67–81, 1979.
5.
BlumR.H., CarterS.K.: Adriamycin, a new anticancer drug with significant clinical activity. Ann. Intern. Med., 80: 249–259, 1974.
6.
BuschmannG., SchumakerR., BuddenR., KüheU.: Evaluation of the effect of dopamine and other catecholamines on the electrocardiogram and blood pressure of rats by means of on-line biosignal processing. J. Cardiovasc. Pharmacol., 2: 777–795, 1980.
7.
BuyniskiJ.P., HirthR.S.: Anthracycline cardiotoxicity in the rat. In: Anthracyclines - Current Status and New Developments, CrookeS.T., ReichS.D. (eds.), pp. 157–170, Academic Press, New York, 1980.
8.
BuyniskiJ.P., HirthR.S.: The surface ECG and cardiac histopathology during chronic administration of anthracycline antitumor agents in rats. In: The Rat Electrocardiogram in Pharmacology and Toxicology, BuddenR., DetweilerD.K., ZbindenG. (eds.), pp. 231–234, Pergamon Press, Oxford, 1981.
9.
CargillC., BachmannE., ZbindenG.: Effect of daunomycin and anthramycin on electrocardiogram and mitochondrial metabolism of the rat heart. J. Natl. Cancer Inst., 53: 481–486, 1974.
10.
DruckM.N., GulenchynK.Y., EvansW.K., GottliebA., SrigleyJ.R., Bar-shlomoB., FeiglinD.H., McEwanP., SilverM.D., MillbaudL., WinterK., HiltolD.J., JablonskyG., MorchJ.E., McLaughlinP.: Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity. Cancer, 53: 1667–1674, 1984.
11.
GilladogaA.C., CorazonM., TanC.C., WolinerN., MurphyM.L.: Cardiotoxicity of adriamycin (NSC-123127) in children. Cancer Chemother. Rep., 6: 209–214, 1975.
12.
HuS.T., BrändleE., ZbindenG.: Inhibition of cardiotoxic, nephrotoxic and neurotoxic effects of doxorubicin by ICRF-152. Pharmacology, 26: 210–220, 1983.
13.
IshikawaK.: Influence of alterations in the hematocrit upon the P wave and the QRS complex. Chest, 69: 762–767, 1976.
14.
JensenR.A., ActonE.M., PetersJ.H.: Electrocardiographic and transmembrane potential effects of 5-iminodaunorubicin in the rat. Cancer Res., 44: 4030–4039, 1984.
15.
JensenR.A., ActonE.M., PetersJ.H.: Doxorubicin cardiotoxicity in the rat: comparison of ECG, transmembrane potential and structural effects. J. Cardiovasc. Pharmacol., 6: 186–200, 1984.
16.
KarnovskyM.J.: A formaldehyde fixative of high osmolarity for use in electron microscopy. J. Cell Biol., 27: 137a, 1965.
17.
KiltyS.E., LepechkinE.: Effect of body build on the QRS voltage of the electrocardiogram in normal men. Circulation, 31: 77–84, 1965.
18.
LeFrakE.A., PithaJ., RosenheimS., GottliebJ.A.: A clinico-pathologic analysis of adriamycin cardiotoxicity. Cancer, 32: 302–314, 1973.
19.
MinowR.A., BenjaminR.S., GottliebT.A.: Adriamycin (NSC 123127) cardiomyopathy - An overview with determination of risk factors. Cancer Chemother. Rep., 6: 195–201, 1975.
20.
MinowR.A., BenjaminR.S., LeeE.T., GottliebJ.A.: QRS voltage change with adriamycin administration. Cancer Treat. Rep., 62: 931–934, 1978.
NierenbergD.W., RausilB.J.: Q-aTc interval as a clinical indicator of hypercalcemia. Am. J. Cardiol., 44: 243–248, 1979.
23.
RichardsonK.C.: Embedding in epoxy resin for ultrathin sectioning microscopy. Stain Technol., 35: 313, 1960.
24.
SurawiczB.: Effect of Ca on the duration of the Q-T interval and ventricular systole in the dog. Am. J. Physiol., 205: 758–789, 1963.
25.
ThatcherC., WhiteP.D.: The electrocardiogram in mixedema. Am. J. Med. Sci., 171: 61–66, 1926.
26.
ToyamaJ., OkadaA., NagataY., OkajimaM., YamadaK.: Electrocardiographic changes in pulmonary emphysema: effects of experimentally induced overinflation of the lungs on QRS complexes. Am. Heart J., 87: 606–613, 1974.
27.
UnverferthD.V., WilliamsT.E., FulkersonP.K.: Electrocardiographic voltage in pericardial effusion. Chest, 75: 157–160, 1979.
28.
VenableJ.H., CoggeshallR.: A simplified citrate stain for use in electron microscopy. J. Cell Biol., 25: 407–408, 1965.
29.
Von HoffD.D., LayardM.W., BasaP., DavisH.L., Von HoffA.L., RozencweigM., MuggiaF.: Risk factors for doxorubicin-induced congestive heart failure. Ann. Intern. Med., 91: 710–717, 1979.
30.
Von HoffD.D., RozencweigM., PiccartM.: The cardiotoxicity of anticancer agents. Semin. Oncol., 9: 23–33, 1982.
31.
VoukydisP.C.: Effect of intracardiac blood on the electrocardiogram. N. Engl. J. Med., 291: 612–616, 1974.
32.
WongT.C.Y., BarzilaiD.C., SmithR.E., McConaheyW.M.: Electrocardiographic voltage changes during hyperthyroidism. Mayo Clin. Proc., 54: 763–768, 1979.
33.
ZbindenG., BrändleE.: Toxicologic screening of daunorubicin (NSC-82151), adriamycin (NSC-123127) and their derivatives in rats. Cancer Chemother. Rep., 59: 707–715, 1975.
